OXFORD, UK: Sensyne Health plc, the British clinical AI technology company, welcomes EY Global Services Limited’s announcement on the intended expansion of its current Health Outcomes Assessment platform by collaborating with Guardtime and Sensyne Health.
The platform is the first of its kind for the healthcare industry and provides an end-to-end solution for outcomes-based contracting – an approach that ties the payment of medicines to the achievement of specific clinical and patient satisfaction benchmarks and efficiency improvements in patient treatment pathways.
Through the planned collaboration, Sensyne Health will add clinical artificial intelligence (AI) and Guardtime will add blockchain technologies to help enable the platform to scale faster, leading to fairer reimbursement and access to novel treatments for patients.
The collaboration will aim to solve one of healthcare’s biggest challenges – accurate and fair patient reimbursement against the actual health outcome provided by healthcare providers and drug manufacturers.
Under the arrangement, Guardtime will run its HSX bridge software, built on the KSI blockchain. Through this technology, healthcare data can be transported securely with a transparent audit trail allowing immutable evidence of how each data element is viewed and used.
Sensyne Health will use its clinical AI platform to evaluate patient health impact. EY teams will bring independent contract assessment, contract management and automated business process experience to allow pharmaceutical companies and healthcare providers to share data and help manage real-world outcomes-based contracts at scale with total transparency and trust.
Lord (Paul) Drayson, Chief Executive Officer of Sensyne Health plc, said: “This new collaboration will position Sensyne at the centre of a technology solution to one of the major challenges facing global healthcare – how to link reimbursement to the benefits provided to patients. We look forward to working with EY, Guardtime and global pharmaceutical companies and payers to help deliver this new capability.”
Dan Matthews, EY EMEIA Life Sciences Leader, said: “We are delighted to be working to deliver the triple win: with life sciences companies increasing access to medicines, health care providers achieving greater efficiency and effectiveness and, most importantly, more patients getting better health outcomes. This is only possible through the combination of novel technologies and a supporting commercial model that allows industry collaboration.”
Mike Gault, Guardtime CEO, said: “Payers, providers and pharma have long aspired to move towards value-based healthcare; this collaboration now makes it possible. Guardtime’s KSI blockchain technology will help ensure patient-level data visibility without compromising data privacy, ensuring all participants can collaborate securely and with confidence. We are excited about the opportunities this collaboration brings to the health industry.”